Regulatory Fate of Cancer Indications in the European Union After Accelerated Approval in the US

被引：1
|
作者：
Petersen, Tonny Studsgaard [1 ,2 ]
Karstoft, Kristian [1 ,2 ]
Sorup, Freja Karuna Hemmingsen [1 ,2 ]
Lund, Marie [1 ,2 ,3 ]
Cramer, Allan [1 ]
机构：
[1] Copenhagen Univ Hosp Bispebjerg & Frederiksberg, Dept Clin Pharmacol, Bispebjerg Bakke 23,2400 Kbh NV, DK-2400 Copenhagen, Denmark
[2] Univ Copenhagen, Dept Clin Med, Copenhagen, Denmark
[3] Statens Serum Inst, Dept Epidemiol Res, Copenhagen, Denmark
来源：
JAMA ONCOLOGY | 2025年 / 11卷 / 01期
关键词：
D O I：
10.1001/jamaoncol.2024.5145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 71
页数：2
相关论文
共 50 条
  • [21] Regulatory and Clinical Experiences with Biosimilar Filgrastim in the US, the European Union, Japan, and Canada
    Chen, Brian
    Nagai, Sumimasa
    Armitage, James O.
    Witherspoon, Bartlett
    Nabhan, Chadi
    Godwin, Ashley C.
    Yang, Y. Tony
    Kommalapati, Anuhya
    Tella, Sri Harsha
    DeAngelis, Carlo
    Raisch, Dennis W.
    Sartor, Oliver
    Hrushesky, William J.
    Ray, Paul S.
    Yarnold, Paul R.
    Love, Bryan L.
    Norris, LeAnn B.
    Knopf, Kevin
    Bobolts, Laura
    Riente, Joshua
    Luminari, Stefano
    Kane, Robert C.
    Hoque, Shamia
    Bennett, Charles L.
    ONCOLOGIST, 2019, 24 (04): : 537 - 548
  • [22] Regulatory requirements for approval of veterinary therapeutics or growth enhancers used in fish production: European Union.
    Alderman, DJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1998, 215 : U51 - U51
  • [23] Accelerated Approval of Cancer Drugs-Righting the Ship of the US Food and Drug Administration
    DiMagno, Sarah S. P.
    Glickman, Aaron
    Emanuel, Ezekiel J.
    JAMA INTERNAL MEDICINE, 2019, 179 (07) : 922 - 923
  • [24] Evaluating time to withdrawal of anti-cancer drug indications that received FDA's accelerated approval
    Hakariya, H.
    Ozaki, A.
    Mulinari, S.
    Moriarty, F.
    Tanimoto, T.
    QJM-AN INTERNATIONAL JOURNAL OF MEDICINE, 2024,
  • [25] Public health implications of differences in US and European Union regulatory policies for breast implants
    Zuckerman, Diana
    Booker, Nyedra
    Nagda, Sonia
    REPRODUCTIVE HEALTH MATTERS, 2012, 20 (40) : 102 - 111
  • [26] REGULATORY LITIGATION IN THE EUROPEAN UNION: DOES THE US CLASS ACTION HAVE A NEW ANALOGUE?
    Strong, S. I.
    NOTRE DAME LAW REVIEW, 2012, 88 (02) : 899 - 971
  • [27] Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
    Cherla, Avi
    Naci, Huseyin
    Kesselheim, Aaron S.
    Gyawali, Bishal
    Mossialos, Elias
    JAMA INTERNAL MEDICINE, 2021, 181 (04) : 490 - 498
  • [28] Overall survival information and population correspondence for FDA cancer accelerated approval indications between 2006 and 2021.
    Benedict, Agnes
    Szabo, Gabor
    Doherty, Bridget
    Martin, Silas
    Marczell, Kinga
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [29] Harmonization of US, European Union, and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals: Is This Possible?
    Schwarz, Sally W.
    Decristoforo, Clemens
    Goodbody, Anne E.
    Singhal, Nikhita
    Saliba, Sarah
    Ruddock, Patrick S.
    Zukotynski, Katherine
    Ross, Andrew A.
    JOURNAL OF NUCLEAR MEDICINE, 2019, 60 (02) : 158 - 166
  • [30] SCIENTIFIC RATIONALE & REGULATORY REQUIREMENTS FOR BIOSIMILARS: US VS. EUROPEAN UNION VS WHO
    Chibane, I
    Amrane, Y.
    Connan, C.
    Mahi, L.
    VALUE IN HEALTH, 2019, 22 : S288 - S288
12345